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Administration of the ovarian steroid estradiol in male and female animals has been shown
to have neuromodulatory and neuroprotective effects in a variety of experimental models.
In the present study, spinal tissues from dermatomes just above (T5–T7, at level) a severe
chronic spinal cord injury (SCI) at T8 were analyzed for expression levels of prodynorphin
(PRDN) and phospho-(serine 369) κ-opioid receptor (KOR-P) in 17 β estradiol (EB)- and
placebo-treated adult male rats. Dynorphin was targeted since (1) it has previously been
shown to be elevated post-SCI, (2) intrathecal injection of dynorphin produces several of
the same adverse effects seen with a SCI, and (3) its increased expression is known to
occur in a variety of different experimental models of central neuropathic pain. A signiﬁcant
elevation of extracellular levels of both PRDN and KOR-P in the placebo-treated SCI group
relative to uninjured surgical sham controls was found in spinal tissues above the injury
level, indicating increased dynorphin levels. Importantly, the EB-treated SCI group did not
show elevations of PRDN levels at 6weeks post-injury. Immunohistochemical analysis of
at level tissues revealed that EB treatment signiﬁcantly prevented a post-SCI increase in
expression of PRDN puncta co-labeling synapsin I, a nerve terminal marker.The dynorphin-
containing terminals co-labeled vesicular glutamate receptor-2 (a marker of glutamatergic
terminals), a ﬁnding consistent with a non-opioid basis for the adverse effects of dynor-
phin.These results support a beneﬁcial role for EB treatment post-SCI through a reduction
in excessive spinal cord levels of dynorphin. Studies manipulating the timing of the EB
treatment post-injury along with speciﬁc functional assessments will address whether the
beneﬁcial effects are due to EB’s potential neuromodulatory or neuroprotective action.
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INTRODUCTION
The effect of circulating blood levels of 17β-estradiol on the devel-
opment of central neuropathic pain in a model of severe chronic
spinal cord injury (SCI) at T8 has been a focus of recent studies in
our laboratory. We have previously reported that the proportion
of ovariectomized (ovx) SCI female rats and placebo-treated SCI
males displaying pain-like behaviors (allodynia) evoked by light
touch or pressure applied to sensitive dermatomes (T5–T8) up
to 6weeks post-injury (67 and 75%, respectively; Hubscher et al.,
2010)was similar to our previous studies on SCImales (69%;Hub-
scher and Johnson, 1999, 2006). In contrast, signiﬁcantly fewer
estrous cycling SCI female rats and 17β-estradiol (EB) treated SCI
male rats showed sensitivity to touch at level (26 and 30%, respec-
tively) up to 6weeks post-SCI (Hubscher et al., 2010). Thus, our
prior studies demonstrate a positive outcome on the development
and/or maintenance of at level (T5–T8) allodynia after treatment
with subcutaneous EB pellets that were implanted prior to the
injury.Note that several different research groups have shownben-
eﬁcial functional outcome of EB treatment in SCI rodent models
for locomotor function, which several studies have shown is due
in part to a reduction in apoptotic cell death (Yune et al., 2004;
Chaovipoch et al., 2006; Sribnick et al., 2006; Ritz and Hausmann,
2008; Kachadroka et al., 2010).
The purpose of the present study is to begin investigating
whether EB acts to diminish the observed sensory disturbances
at level post-SCI by acting upon some of the adverse neuromodu-
latory changes that disrupt normal homeostaticmechanisms in the
tissues just above the level of lesion (region of cord supplying the
hypersensitive dermatomes). Dynorphin, an endogenous κ opioid
agonist (Chen et al., 2007),has been chosen for the study of adverse
at level neuromodulatory changes because high tissue levels of
dynorphin in spinal cord has been shown in different experimen-
tal models of neuropathic pain, including nerve injuries by spinal
nerve ligation (SNL) at L5, L6, and S2 (Malan et al., 2000; Lai
et al., 2006), inﬂammatory pain models in rats induced by injec-
tions of the complete Freund adjuvant (CFA; Millan et al., 1985;
Calza et al., 1998; Zhang et al., 1998; Lin et al., 2010) or collagen
II (Persson et al., 1994), cancer pain produced by intramedullary
injection of sarcoma cells in the femur of mice (Honore et al.,
2000), and excitotoxic injury of spinal cord by intraspinal injec-
tion of quisqualic acid (Abraham et al., 2001). Several studies
to-date have also reported increased tissue levels of dynorphin,
just above, at and below the level of SCI relative to intact con-
trols during the acute/sub-acute phase post-lesion (Faden et al.,
1985; Przewlocki et al., 1988; Sharma et al., 1992; Tachibana
et al., 1998; Abraham et al., 2001). Moreover, neuropathic pain
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lasting 70 days was induced with a single intrathecal injection of
dynorphin in spinally intact animals, suggesting that high tissue
levels of dynorphin can result in long-lasting post-injury changes
(Vanderah et al., 1996; Laughlin et al., 1997). In addition, the
pronociceptive role of increased dynorphin levels in spinal tissues
in post-SNL pathophysiology is conﬁrmed when paw withdrawal
latencies and response thresholds in prodynorphin (PRDN) gene
knockout mice return to normal by day 10 (1) after L5/6 SNL,
which coincides with the upregulation of PRDN, and (2) after
the intrathecal application of dynorphin antiserum also in a late
phase in wild type mice with SNL (Wang et al., 2001). In a
study using an inﬂammatory pain model induced by CFA injec-
tion, intrathecal administration of MK-801, a non-competitive
blocker of N -methyl-d-aspartate receptors (NMDAR) suppressed
the upregulation of PRDN mRNA as well as the hyperalgesic
response (Zhang et al., 1998) supporting the argument that dynor-
phin upregulation is needed for induction of the hyperalgesic
response.
Accordingly, we hypothesize that (a) an increase in the expres-
sion of spinal cord PRDN will also be present during the chronic
phase of the current SCI (T8) model of at level (T5–T8) allo-
dynia in male rats and (b) this increased expression of PRDN
will be reversed in male rats which receive systemic EB treatment
(slow release pellets at serum levels that simulate proestrus) prior
to injury. Hence, the effect of the injury and the EB treatment
on PRDN levels 6 weeks following a contusion at T8 spinal cord
was investigated ﬁrst by Western blot using the T5–T6 at level
spinal tissue and subsequently with immunohistochemistry using
the T7 at level spinal tissue. To determine the levels of extracellu-
lar dynorphin in spinal tissues, the phosphorylation of κ-opioid
receptor (KOR) at serine 369 was measured. Phosphorylation
has been shown to occur in response to prolonged activation by
dynorphin, in a concentration dependent manner in the pres-
ence of exogenous κ-speciﬁc agonist, U50,488 (Appleyard et al.,
1997; McLaughlin et al., 2003). To gain additional insights into
potential mechanisms involved, the phenotypes and connectivity
of dynorphin-containing neurons were examined using immuno-
histochemistry, including PRDN expression in neuronal soma and
nerve terminals in laminae I and II, which contain important
nociceptive circuits (Todd, 2002).
MATERIALS AND METHODS
Twenty male Wistar rats (four surgical shams, eight placebo-
treated SCI, and eight EB-treated SCI) approximately 60–70 days
old and weighing 200–250 g, were housed individually on a 12-h
light–dark cycle and handled daily. One additional non-injured
male rat was used for obtaining spinal cord tissues for electron
microscopy.All animal procedures were reviewed and approved by
the InstitutionalAnimalUse andCareCommittee at theUniversity
of Louisville, School of Medicine.
EB TREATMENT
One week prior to SCI (to mirror the procedures in our preceding
behavioral study – Hubscher et al., 2010), hormone and placebo
pellet insertion was done via a small incision in the skin of the
neck just behind the right ear under brief isoﬂuorane anesthe-
sia. Sixteen animals were given subcutaneous implants of either
EB (60-day release, 0.25mg/pellet; IRA, Sarasota, FL, USA; eight
rats) or placebo (eight rats) pellets as previously described (Reed
et al., 2009). All experimenters were blinded to the content of the
implant. In four sham animals,which did not receive any implants,
laminectomy was done without any contusion to the spinal cord.
The EB pellets are expected to yield continuous serum hormone
levels that are reached during proestrus (Kalra and Kalra, 1974;
Nequin et al., 1979; Samuel et al., 1998; Dantas et al., 2002). Fur-
thermore, a previous study from this laboratory showed that the
use of these subcutaneous placebo and EB implants in ovariec-
tomized female rats had resulted in the presence of cells in the
vaginal smears that resembled the diestrus and proestrus stages,
respectively (Reed et al., 2009).
CONTUSION INJURY
Spinal cord contusions were carried out using a protocol described
previously (Hall et al., 2010). Brieﬂy, rats were anesthetized with
a mixture of ketamine (80mg/kg of body weight) and xylazine
(10mg/kg of body weight) injected intraperitoneally. The Inﬁnite
Horizon Impactor device (Precision Systems and Instrumentation,
LLC, Fairfax, VA, USA; Scheff et al., 2003) was used to produce a
severe injury at T8 spinal cord exposed after T7 laminectomy,with
a pre-set force of 225 kdyn and a 1-s dwell time. During the post-
operative period, all animals were monitored three times daily and
were given an analgesic (Ketoprofen, 2.5mg/kg, sc, twice daily) for
2 days, and Gentamicin (5mg/kg, sc) for 4 days to prevent bladder
infections.
BEHAVIORAL MEASUREMENTS
Behavioral testing of all rats for sensitivity to normally innocuous
stimuli (light touch and gentle squeeze/pressure) to monitor allo-
dynia was done in a dedicated facility as previously described (Hall
et al., 2010). Baseline measurements were obtained pre-injury
for comparison with those obtained during the 6-week post-SCI
period. For each testing session, a total of 10 stimuliwere applied to
the dorsolateral trunk at and just above the level of lesion (T5–T8)
alternating between the right and left sides (ﬁve each). After each
stroking with a number 5 paintbrush (a 17 g stimulus force), the
presence or absence of any one of three types of pain-like behavior
(freeze, escape, or grab/push probe with their forepaws) was docu-
mented (Hubscher and Johnson, 2006; Hubscher et al., 2008; Hall
et al., 2010). Note that for an animal to be considered responsive
to a stimulus, the animal has to show a pain-like response during
at least 60% of the trials in a given session (Hubscher and John-
son, 2006; Hubscher et al., 2008). For those animals not responsive
to the brush stroke, a gentle squeeze/pressure (a 60-g mechanical,
normally innocuous stimulus) was tested using Adson tissue for-
ceps applied to T5–T8 dermatomes on the dorsolateral trunk ﬁve
times each side using the 60% criteria.
A 10-point scale (Hall et al., 2010) was used for calculating the
allodynia score for each session. The criterion for allodynia is a
score higher than 0 on 3–5weeks, two of which must be on con-
secutive weeks (to ensure that the response was consistent, and not
a one-time occurrence). Scores of 1, 2, and 3 were assigned respec-
tively for freeze, escape, or grab/push probe responses to gentle
squeeze. An additional three points are added if the same response
occurred with the brush stroke, a gentler stimulus. Whenever
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responses to brush strokes occurred, we did further testing with
Semmes–Weinstein monoﬁlaments. Points were added for lower
thresholds thereby accounting for sensitivity differences. A mean
allodynia score is then assigned to each SCI rat, based on the values
of ﬁve scores obtained from the second week (when allodynia ﬁrst
develops) through the sixth week post-SCI.
TISSUE PROCESSING
After completion of the chronic 6weeks post-injury period, each
animal was euthanized with a lethal dose of urethane (2.0 g
urethane/kg of body weight). Enough serum was collected for
radioimmunoassay of duplicate samples for serum EB levels,
which were then coded and sent to the Ligand Assay and Analysis
Core Laboratory at the Center for Research in Reproduction at the
University of Virginia Health Sciences Center. Spinal cord tissues
were removed forWestern blot analysis by cutting a block contain-
ing two vertebrae (T4/5) and extruding the cord segments (T5/6)
by injecting ice-cold saline, which was then immediately frozen in
liquid nitrogen and stored at −80˚C. The remainder of the spinal
cord fromT7 toT13was removedwith intact vertebral columnand
placed promptly in 4% paraformaldehyde for 2–4 days at 4˚C. The
spinal cord was dissected out after laminectomy, cut into segments
for immunohistochemistry (T7) and the lesion epicenter recon-
struction (T8), transferred into 30% sucrose solution for at least
48 h at 4˚C for cryoprotection, sectioned at 30 μm thickness on a
cryostat, mounted on positively charged slides (Fisher Scientiﬁc,
Pittsburgh, PA, USA) and stored at −20˚C.
For calculating white and gray matter sparing, the slides con-
taining sections from the epicenter (T8) were stained using the
Klüver–Barrera method to separately visualize white and gray
matter as previously described (Hall et al., 2010). The areas of
white and gray matter were estimated using Spot Imaging soft-
ware (Spot Imaging Solutions, Sterling Heights, MI, USA). The
percent sparing was calculated by dividing the total areas of gray
and white matters at the epicenter by the total areas of rela-
tively normal gray and white matters at 1mm rostral to the
epicenter.
WESTERN BLOT
A modiﬁcation of previously described protocol was used (Dogra
et al., 2006). Each spinal cord segment (T5–T6) from sham and
chronic lesioned rats with and without EB treatment, representing
20 animals, was suspended (1mg weight per 20μl) into ice-cold
lysis buffer (50mM Tris–Cl (pH 7.4), 200mM NaCl, 0.3% NP-40,
2mg/ml leupeptin, 2mg/ml aprotinin, 1mM phenylmethylsul-
fonylﬂuoride, 0.5mg/ml benzamidine, 1mM dithiothreitol, and
1mM sodium orthovanadate, 50mM sodium ﬂuoride, 10mM β-
glycerophosphate) by mechanical grinding in a glass homogenizer.
A clear extract was then obtained for Western blot after centrifu-
gation at 4˚C at 14,000 RPM. The protein concentration of each
sample was determined using a Bio-Rad protein assay kit (Bio-Rad
Laboratories, Inc., Hercules, CA, USA). Each sample containing
50μg of protein was then loaded and electrophoresed with a 10%
SDS gel with 20 lanes using the Protean® II xi Cell system (Bio-
Rad Laboratories, Inc., Hercules, CA, USA). The proteins in gel
were transferred to nitrocellulose paper. Only those blots show-
ing uniform transfer were later incubated overnight in primary
antibodies at appropriate dilutions (Table 1). Horseradish perox-
idase linked secondary antibodies (1:1000), goat anti-rabbit IgG
and goat anti-mouse IgG (Cell Signaling Technology, Beverly,MA,
Table 1 | List of primary antibodies.
Antigen Immunogen Manufacturer, species,
type, catalog number
Dilution used Application
α-ER KLH conjugated synthetic peptide (last
15 amino acids of rat α-ER)
Upstate, rabbit antiserum, 06-935 1:1000 I.H.
Dynorphin C-terminus of proenkephalin B of
human origin.
Santa Cruz Biotechnology, Inc., goat
polyclonal, sc-46313
1:500 W.B.
KOR-P Synthetic polypeptide around residue
S369 in rat KOR
Abcam, rabbit polyclonal, ab63511 1:500 W.B./I.H.
β-tubulin N-terminus of human tubulin Abcam, rabbit polyclonal, ab18587 1:1000 W.B.
PRDN Synthetic sequence (amino acids
245-258 of rat PRDN)
Neuromics, guinea pig polyclonal,
GP10110
1:500 I.H.
NeuN Puriﬁed cell nuclei from mouse brain Millipore, mouse monoclonal,
MAB377
1:1000 I.H.
CGRP Full length rat protein conjugated to
thyroglobin
Abcam, rabbit polyclonal, ab49873 1:2000 I.H.
VGLUT1 C-terminus 17 residue synthetic
peptide of rat VGLUT1
Novus Biologicals, rabbit antiserum,
NB 100-1837
1:2000 I.H.
VGLUT2 Recombinant protein from rat VGLUT2 Millipore, mouse monoclonal,
MAB5504
1:500 I.H.
GAD 67/GAD 65 Synthetic peptide (identical in GAD67
and GAD65) conjugated to KLH
Abcam, rabbit polyclonal, ab49832 1:1000 I.H.
Synapsin I Full length native protein puriﬁed (cow) Abcam, rabbit polyclonal, ab8 1:1000 I.H.
MAP-2 Bovine Microtubule associated protein Sigma, mouse monoclonal, M1406 1:1000 I.H.
www.frontiersin.org February 2012 | Volume 3 | Article 28 | 3
Gupta and Hubscher Estradiol effect on dynorphin post-injury
USA), and bovine anti-goat IgG (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) were used.
After incubation with secondary antibodies and washes with
phosphate buffered saline (PBS, pH 7.4; 10× PBS contained
1.37M NaCl, 14.7mM KH2PO4, 78.1 mM Na2HPO4, and 2 g
KCl), the membranes were treated with chemilumiscent horserad-
ish peroxidase detection reagent (HyGLO™; Denville Scientiﬁc,
Inc., Metuchen, NJ, USA) and exposed to autoradiography ﬁlm
(Denville Scientiﬁc, Inc., Metuchen, NJ, USA). After every West-
ern blot with a speciﬁc antibody against a speciﬁc antigen, the
blots were washed with a stripping buffer (0.2M Glycine, 10%
Tween 20, 0.1% SDS, pH 2.2) to remove bound antibodies, and
re-probed with an anti-rabbit β-tubulin antibody as a control. β-
tubulin bands were seen at 50 kDa as expected. ImageJ 1.40 (ver.
1.40, NIH) was used to quantify proteins in the Western Blot. The
protein levels were expressed as the total optical density (OD)units
in a band, which were normalized by dividing with the total OD
units in the corresponding β-tubulin bands.
IMMUNOHISTOCHEMISTRY
For immunohistochemistry, sufﬁcient T7 at level tissues (based
upon close proximity to T8 contusion) were available from four
sham, ﬁve SCI animals with placebo treatment and four SCI rats
with EB treatment. The experimenter was blinded to the type
of implant. A modiﬁcation of our previously published protocol
was used (Cothron et al., 2008). Each slide contained ﬁve 30μm
sections, which were at least 120 μm apart. All slides were heated
at 80˚C in 10mM sodium citrate buffer for 35min for antigen
retrieval (Jiao et al., 1999) before each immunohistochemistry.
After cooling, slides were washed with 0.1M Tris buffered saline
(TBS containing 150mM NaCl, 50mM Tris, pH 7.4) three times,
for 5min and warmed on a slide warmer for 60min at 37˚C. To
block the non-speciﬁc antigenic sites, slides were incubated for
2 h in 0.1M TBS with 5% donkey and 5% goat sera. For double
labeling studies, sections were incubated in a mixture of two pri-
mary antibodies (Table 1) from different species at 4˚C for 48 h,
and washed with 0.1M TBS with detergent (0.25% Triton-x, TBS-
T) for 30min, six times. Slides were then incubated in a mixture
of secondary antibodies for 2 h at room temperature followed by
six washes for 30min with TBS-T. Finally, the slides were cover-
slipped with Fluoromount G (SouthernBiotech, Birmingham,AL,
USA), and stored in the dark at 4˚C.
Twenty 1μm thick optical slices of confocal images in z-
axis were collected with a Nikon Eclipse® microscope, which
were rendered to produce a ﬁnal XY image. Cells and
puncta were counted using NIH software ImageJ which was
upgraded with a plugin (Cell Counter) downloaded from NIH
(http://rsbweb.nih.gov/ij/plugins/). For the purpose of counting,
a single optical section having 1μm thickness from each Z-stack
was used to avoid confusion between co-localization and overlap
of structures. Each image was digitally magniﬁed for a clear visu-
alization before counting by increasing the pixel sizes of X and
Y dimensions by 7- to 10-fold with Adobe Photoshop®. Up to
three sections were used to generate a mean count from each ani-
mal. Each section on a given slide was at least 120μm apart from
the others to avoid double counting the same structures. Count-
ing was done separately in two regions, superﬁcial laminae (I and
II) and the remaining laminae (III–X) using boundaries as illus-
trated in Paxinos’ Rat Brain Atlas (Paxinos and Watson, 1998).
The settings for exposure, brightness and contrast were adjusted
before each image acquisition to get a crisp and clear boundary
of histological structures. Negative controls in all studies con-
sisted of replacing the antiserum with the non-immune serum
of the host animals. In addition, PRDN antiserum, after blocking
in the presence of 1μg/ml of blocking dynorphin peptide (Neu-
romics, Edina, MN, USA, Cat# P10116) in ﬁnal diluted antibody,
was used as an additional negative control for testing the speciﬁcity
of PRDN antibody. There was an absence of speciﬁc staining in
all negative controls. To prevent the non-speciﬁc labeling, the ﬁnal
concentrations of all antibodies were maintained between 0.5 and
5μg/ml. The secondary antibodies used were DyLight 488, 594
conjugated F(ab′)2 fragments of goat or donkey antibodies against
IgG of different species (Jackson ImmunoResearch, Inc.). F(ab′)2
fragments was used in place of whole antibodies containing Fc
portions, which bind in a non-speciﬁc manner to the Fc receptors
expressed by the macrophages (Diamond and Yelton, 1981) that
commonly migrate to the injury sites. The use of better perfor-
mance ﬂurochromes, DyLight 488 and Dylight 594, was adopted
to minimize the photobleaching.
ELECTRON MICROSCOPY
A single male rat with intact spinal cord was perfused transcar-
dially with 100ml of 4% formaldehyde and 0.25% glutaraldehyde
in phosphate buffer under urethane anesthesia. After perfusion,
the spinal cord (T6–T7) was immediately removed and post-ﬁxed
overnight in 4% formaldehyde, 0.25% glutaraldehyde at 4˚C. For
nickel-enhanced 3,3′diaminobenzidine (Ni-DAB) immunohisto-
chemistry, 50μm sections were pre-incubated in 10% normal
goat serum for 30min. Sections were then incubated overnight
with antibodies against PRDN or VGLUT2 (Table 1) contained in
5% normal goat serum. The next day after three, 10min washes
in PBS, the sections were incubated in appropriate biotinylated
secondary antibodies (200× dilution). Following 1 h of incuba-
tion, sections were washed again three times for 10min in PBS,
and later incubated in ABC solution (Elite Standard ABC kit,
Vector Laboratories, Burlingame, CA, USA). The sections were
then washed once in 0.1M sodium acetate (pH 6.0) and twice
with PBS for 10min each. Equal volumes of 0.1% DAB and 3%
nickel ammonium sulfate in 0.1M sodium acetate were mixed
and 3μl/10ml of hydrogen peroxide was added. Sections were
immersed in Nickel/DAB solution containing hydrogen peroxide
for 5min and then washed once with 0.1M sodium acetate (pH
6.0) and twice with PBS for 10min each. The sections were then
stored in PBS at 4˚C before embedding them in LX112 epon resin
for electron microscopy. Ultrathin histological sections (800Å)
were cut and stained with uranyl acetate. Stained sections were
mounted on a 200 mesh copper grid and viewed under Philips
CM-12 transmission electron microscope with an operating volt-
age of 80 kV. Electron micrographs were obtained under 10,000×
to 19,500× magniﬁcations.
STATISTICAL ANALYSIS
A two-way ANOVA followed by Tukey HSD post hoc pairwise t -
tests using SPSS software (SPSS Inc.,Chicago, IL,USA)was used to
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analyze the effect of the injury and the EB treatment on the expres-
sion levels of various proteins obtained by the Western blot study.
The confocal data was analyzed by the GraphPad Prism 5.0 (La
Jolla, CA, USA). Pearson Correlation test was done to study dif-
ferent correlations. The value of p for rejection of null hypothesis
was set at 0.05 for all analyses.
RESULTS
SEVERITY OF INJURY
The actual force of compression of the spinal cord at T8,measured
at the tip of the impounder, averaged 227± 3.7 kdyn with an aver-
age displacement of 1.2± 0.1mm in placebo-treated animals and
225± 2.1 kdyn with an average displacement of 1.4± 0.1mm in
EB-treated animals. The number of animals used initially in this
study including 4 shams was 20; however, 1 animal in the EB-
treated group was excluded from the data analysis as the values
of initial parameters of injury from Inﬁnite Horizon Impactor did
notmeet ourminimumcriteria for the desired injury severity (dis-
placement above 1.0mm which is necessary to obtain a “severe”
SCI and thus allodynia). The average percent white matter sparing
at the lesion epicenter (T8) was 4.2± 1.7 and 5.5± 0.8%, respec-
tively in placebo (n = 8) and EB-treated (n = 7) rats. The mean
percent gray matter sparing was 0.21± 0.21 and 0.24± 0.17% in
placebo and EB-treated SCI rats, respectively. The low percent
sparing of gray and white matters indicates the presence of severe
injuries in these animals, which is expected from an injury force
of 225 kdyn with a dwell time of 1 s.
SYSTEMIC EB LEVELS AFTER SUBCUTANEOUS PELLET TREATMENT
The mean serum EB level in male rats receiving subcuta-
neous EB pellets (7 weeks post-implant; 6 weeks post-SCI) was
50.5± 13.1 pg/ml, which is signiﬁcantly (p< 0.01) higher than
the mean level of 9.4± 4.0 pg/ml observed in the rats that had
received subcutaneous pellets containing vehicle alone. The values
of EB levels in the treated group were similar to those seen during
the proestrus phase in female rats (Nequin et al., 1979; Kramer
and Bellinger, 2009; Santmyire et al., 2010).
BENEFICIAL EFFECT OF SYSTEMIC EB TREATMENT ON PAIN-LIKE
BEHAVIOR IN SCI RATS
At level (T5–T8) allodynia developed in seven out of eight male
animals in the placebo-treated group. The high incidence of allo-
dynia in adult male rats with a severe T8 contusion in the placebo-
treated group is consistent with our previous studies (Hubscher
and Johnson,1999,2006;Hall et al., 2010;Hubscher et al., 2010). In
contrast, only three from the group of seven EB-treated male ani-
mals (with proestrus-like EB levels for proof of principle) showed
allodynia. A binomial proportion test corrected for small sample
sizes (Siegel and Castellano, 1988) showed signiﬁcant differences
between the incidence of allodynia in the two groups (p< 0.01).
THE WESTERN BLOT STUDY OF PRDN AND KOR-P EXPRESSION AT
LEVEL
A two-way ANOVA revealed signiﬁcant main effects of injury
[F(1,16)= 16.35, p = 0.001] and the EB treatment on the
spinal cord (T5–T6) levels of PRDN [F(1,16)= 12.53, p< 0.005;
Figure 1A]. Tukey HSD post hoc test further revealed that
injury signiﬁcantly increased tissue levels of PRDN, which was
signiﬁcantly reduced by EB pretreatment (p< 0.01, both).
A signiﬁcant main effect of injury on tissue levels of KOR-
P in the spinal cord [F(1,16)= 8.73, p< 0.01] was also seen
(Figure 1B). However, a main effect of EB treatment on KOR-P
levels was not detectable, which may be attributed to the rela-
tively small sample size of the shamgroup of animals. Signiﬁcantly,
higher spinal cord (T5–T6) levels of KOR-P were observed in SCI
rats with placebo treatment in comparison to the sham animals
(p< 0.01). The Pearson correlation analysis revealed a signiﬁcant
positive correlation between the tissue levels of KOR-P and PRDN
(p = 0.001, r = 0.72, Figure 1C), indicating that the changes in
KOR-P levels are paralleled by changes in PRDN levels in the spinal
cord tissues after the SCI.
THE IMMUNOHISTOCHEMICAL STUDY OF PRDN EXPRESSION AT LEVEL
Figure 2 shows PRDN expression at T7 (the typical example
shown is from SCI rats with placebo treatment). The magniﬁed
image (Figure 2C) of the superﬁcial laminae shows co-expression
of PRDN in NeuN labeled neurons. Note the puncta-like pro-
ﬁle of PRDN expression (Figure 2C), which is consistent with
its expression within nerve terminals, dendrites, and axons. No
signiﬁcant co-expression with dendritic marker microtubule asso-
ciated protein-2 was seen (data not shown). However, PRDN
co-expression with the nerve terminal marker synapsin I (De
Camilli et al., 1983) was seen (Figure 2E). In total, 887 (mean:
177± 17 per 1μm thick optical section) out of 1421(mean:
285± 49 per section) PRDN-IR puncta (∼62%) in all lami-
nae (n = 5; one section counted per placebo-treated SCI animal)
showed co-expression with synapsin I.
To study the phenotype of dynorphin terminals, double
labeling was done with antibodies against vesicular glutamate
transporter1 (VGLUT1) and vesicular glutamate transporter2
(VGLUT2), which are markers for glutamatergic terminals (Fre-
meau et al., 2004), and glutamate decarboxylase 67/glutamate
decaboxylase 65 (GAD67/GAD65), which is the marker for the
inhibitory GABAergic terminals (McLaughlin et al., 1975). Only
VGLUT2 and PRDNco-expressionwas seen (Figure 2F). A total of
467 (mean: 93± 8 per section) PRDN-/VGLUT2-double labeled
puncta were present among 1263 (mean: 253± 18 per section)
PRDN-IR puncta, (∼37%), which is based on counts from all
laminae (n = 5; one section per animal).When considered in com-
bination with our ﬁnding that∼62% of PRDN-IR puncta co-label
synapsin I, it is estimated that ∼60% (37 of 62%) of dynorphin
terminals at level are glutamatergic. Since dynorphin expression
in spinal cord is mostly within the interneurons, which is indi-
cated by previous studies showing the lack of effect of bilateral
dorsal rhizotomy (Botticelli et al., 1981) or complete mid-thoracic
transection (Goldstein and Ghazarossian, 1980) on the dynorphin
contents of the spinal cord, it is contended that VGLUT2/PRDN-
IR puncta in spinal cord most likely represent the terminals from
interneurons.
The lack of PRDN co-expression with GAD67/GAD65 (data
not shown) indicates the absence of a signiﬁcant number
of inhibitory dynorphin terminals. A signiﬁcant number of
GAD67/GAD65-IR puncta were however found to be juxtaposed
to PRDN-IR cell bodies and puncta, consistent with inhibitory
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FIGURE 1 | (A,B)Western blot analysis of at level (T5–T6) spinal cord 6weeks
following spinal cord injury (SCI) in male rats shows prodynorphin (PRDN)
band at ∼26 kDa and the phospho-(serine 369)-κ-opioid receptor (KOR-P)
band at ∼43 kDa. (A)The tissue levels represented by PRDN band shows a
signiﬁcant elevation (∼164%) post-SCI in rats with placebo treatment
(*p<0.01). The increased PRDN levels in SCI rats was signiﬁcantly reversed
in the group of male rats having proestrus-like serum levels of 17β estradiol
(EB; Φ, p<0.01). (B) Spinal cord level of KOR-P was signiﬁcantly elevated
(∼151%) in the placebo-treated SCI animals in comparison to the shams
(*p<0.01). The KOR-P levels after EB treatment were not found to be
signiﬁcantly different from those in either the sham or the placebo-treated
group. (C) Depicts the presence of a positive correlation between the
normalized OD (optical density) units representing the tissue levels of PRDN
and KOR-P in the at level spinal cord. The total OD units of PRDN and KOR-P
bands were normalized after division with the respective OD levels of
β-tubulin (50 kDa band). All data are represented as mean±SEM of the
normalized OD values, and were analyzed by ANOVA. n=4, Sham; n=8,
SCI+placebo; n=7, SCI+EB.
inputs to dynorphin neurons. A similar conclusion was reached
previously based on anultrastructural analysis (Cho andBasbaum,
1989).
Double labeling with antibodies for different estrogen recep-
tors (ERs), ERα, ERβ, and G-protein coupled estrogen receptor-1
(GPER-1)/G-protein coupled receptor 30 (GPR30) antibodies in
T7 spinal tissues revealed only PRDN/ERα co-expression, which
was seen predominantly in laminae I and II (Figure 2D; data is
not shown for other antibodies). PRDN/ERα co-expression was
shown previously in the intact lumbar and sacral spinal cord seg-
ments of female rats (Gintzler et al., 2008). The co-expression of
PRDN and ERα provides a morphological basis for the effect of EB
treatment on the tissue levels of PRDN in the at level spinal cord.
ELECTRON MICROSCOPIC STUDY OF PRDN-, VGLUT2-IR EXPRESSION
The electron microscopic images conﬁrm PRDN labeling of vesi-
cles in the nerve terminals, endoplasmic reticulum,andmyelinated
axons (Figures 3A–D). The expression within nerve terminals and
axons is consistent with the puncta- and ﬁber-like proﬁles seen in
the confocal images (Figure 2C). In a magniﬁed view of a synap-
tic nerve terminal labeled by PRDN (Figure 3D), the synaptic
cleft is seen ﬁlled with DAB-Ni precipitate (white arrowheads),
which may represent diffusion of dynorphin after its release. The
presence of post-synaptic density is consistent with the excitatory
phenotype of dynorphin nerve terminals. Notably, PRDN labeling
is absent from the dendrites,which is consistentwith our immuno-
histochemical analysis. VGLUT2 speciﬁc DAB-Ni labeling is seen
within dendrites, axons, and vesicles inside the nerve terminals
(Figures 3E,F).
PRDN EXPRESSION IN SUPERFICIAL (I–II) VS. DEEPER LAMINAE (III–X)
The frequent co-expression of ERα/PRDN in superﬁcial laminae
(typical examples in Figure 2) indicates the possibility that EB
treatment may affect the dynorphin expression of neurons in lam-
inae I and II, which contains important nociceptive circuits. To
study the effect of systemic EB treatment on PRDN expression
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FIGURE 2 | PRDN expression immediately above the level of injury at
T7 (at level) is seen in neuronal cell bodies and nerve terminals
(C,E,F).The confocal image (A) shows a typical spinal cord section from
SCI rat with placebo treatment, double labeled with antibodies against
neuronal marker NeuN and PRDN at T7. The schematic in (B) shows
organization of different mid-thoracic laminae in rats, based on the “The
Rat Brain in Stereotaxic Co-ordinates” by Paxinos andWatson (1998). The
white curved lines in (A) demarcates superﬁcial laminae I and II from the
deeper laminae. The magniﬁed image (C) from the boxed portion from the
superﬁcial laminae (SL) in image (A) reveals PRDN expression within
neuronal soma (yellow arrows). Magniﬁed image (C) also reveals that a
substantial amount of PRDN immunoreactivity at level has a puncta-like
proﬁle. A portion of PRDN-IR puncta is arranged in a ﬁber-like fashion
(yellow arrowheads) suggestive of expression in axons. (D) Shows the
co-localization of PRDN and estrogen receptor α (ERα) in SL (yellow
arrows). Image (E) shows the co-expression of nerve terminal marker,
synapsin I within the PRDN-IR puncta (shown in deep laminae (DL), yellow
arrows). (F) PRDN-IR puncta is shown to co-express glutamatergic marker
vesicular glutamate transporter 2 (VGLUT2). Image in (a) shows a typical
absence of speciﬁc labeling in a section at T7 from SCI animals with
placebo, when primary antibodies (PRDN and NeuN) were substituted
with non-immune sera from the respective host animals. Images shown
are typical of sham, SCI+placebo and SCI+EB rats (n=4–5 each). For
consistency, only images from the SCI+placebo group of male rats are
shown. Co-localizations [yellow arrows in (C,F)] are also seen in XZ andYZ
planes passing through the blue lines. Abbreviations are as in Figure 1.
within neurons in laminae I and II, counts of PRDN-/NeuN-IR
neurons were compared between the superﬁcial laminae (laminae
I–II) and the rest of the gray matter (laminae III–X; Figure 4A). A
two-way ANOVA revealed signiﬁcant main effects of the region
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FIGURE 3 | Representative electron microscopic images ofT7 spinal
cord sections from an uninjured animal illustrate immunocytochemical
staining of PRDN (A–D) andVGLUT2 (E,F) visualized with the
nickel-enhanced diaminobenzidine (DAB-Ni) reaction. Images in (B,D,F)
illustrate at higher magniﬁcation the boxed portions indicated in (A,C,E),
respectively. PRDN labeling is seen in the cytoplasm of neurons [(A) nucleus
indicated, Nu] where DAB-Ni is associated with endoplasmic reticulum [white
arrowheads (B)]. PRDN is also seen in axon terminals (At) where DAB-Ni
surrounds synaptic vesicles [white arrows (D)]. PRDN-labeled terminals
contact the unlabeled dendrites [Den, black arrows point to the post-synaptic
density, white arrowhead indicates synaptic cleft ﬁlled with more intense,
DAB reaction from released dynorphin (D)]. (D) PRDN-IR rounded vesicles
(white arrows) are seen. Light PRDN labeling of myelinated axons is also seen
[black arrowheads (C,D)]. (E,F) VGLUT2 labeling is seen in myelinated axons
(black arrowheads), axon terminals (At), and dendrites (Den). (F) VGLUT2
labeled terminals contact VGLUT2 labeled dendrites (black arrows indicate the
synaptic cleft). The scale bars measure 2μm in (A) and 1μm in (C,E).
Abbreviations are as in Figures 1 and 2.
[laminae I and II vs. the rest of the gray matter, laminae III–
X; F(1,14)= 29.7, p< 0.01] and the treatment groups [placebo
vs. EB pellets; F(1,14)= 6.56, p< 0.03]. There was a signiﬁcantly
higher number of PRDN-/NeuN-IR neurons in laminae I to II
in comparison to the rest of the gray matter (laminae III–X) in
both groups of SCI rats (p< 0.05 for both comparisons; 4.5 times
higher in laminae I and II in the placebo group). Comparisons
of speciﬁc groups using t -tests showed a signiﬁcant drop in the
number of PRDN-/NeuN-IR neurons by 48% in laminae I to II
in SCI rats after EB treatment (p< 0.05). Note that we did not
include the sham animals in this analysis because the neuronal cell
loss, which affects the two SCI groups (those with placebo and EB,
but not the sham group), could confound the analysis. Moreover,
based on Western blot expression, an increase in the counts of
PRDN positive NeuN neurons and/or immunoreactivity intensity
was anticipated after the injury in the placebo treatment group. A
two tailed t -test, with the assumption of equal variance, showed
an absence of any signiﬁcant differences in counts observed in
the sham group (31/section) vs. the SCI placebo treatment group
(27/section; p> 0.05).
The effect of EB treatment on dynorphin expression in nerve
terminalswas examinedby analyzing counts of synapsin I-/PRDN-
IR puncta (Figure 4B). The two-way ANOVA revealed signiﬁcant
main effects of the region [F(1,14)= 11.3, p< 0.01] and the treat-
ment group [F(1,14)= 23.5, p< 0.01] on the counts of synapsin
I-/PRDN-IR puncta. Further post hoc comparisons showed signif-
icantly lower counts of synapsin I-/PRDN-IR puncta in laminae
I–II (p< 0.05) and laminae III–X (p< 0.01) in animals with
the subcutaneous EB pellets vs. the placebo pellets. Decreased
counts of synapsin I-/PRDN-IR puncta following EB treatment is
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FIGURE 4 | (A) In the superﬁcial laminae I–II (SLI-II), signiﬁcantly higher
counts (y -axis) of PRDN-/NeuN double labeled neuronal soma are present
in the placebo-treated vs. the EB-treated SCI animals (*p<0.05). The
number of PRDN-/NeuN double labeled cells is signiﬁcantly more in SLI-II
as compared to the deeper laminae, III–X (DLIII-X) in placebo (φ, p<0.01)
and EB-treated (ρ, p<0.01) groups of SCI animals. (B) Signiﬁcantly higher
counts of synapsin I-/PRDN-IR puncta-like proﬁle, representing dynorphin
nerve terminals, are present in the placebo-treated SCI group as compared
to the EB-treated SCI group in both regions, the SLI-II and DLIII-X
(*p<0.05, for both). Before counting, the gray matter was divided into SL
I-II and DL III-X based on the “The Rat Brain in Stereotaxic Co-ordinates”
by Paxinos andWatson (1998), as shown in the schematic in Figure 2B. A
complete optical section (1μm) taken from the center of stacks of
confocal images was counted. Counts shown on the x -axis are
mean±SEM per section (n=4–5), and was analyzed by a two-way
ANOVA. Abbreviations are as in the Figure 1.
consistent with reduced dynorphin content in the nerve terminals
indicating a potential reduction in the dynorphin release.
DISCUSSION
The current study reveals a beneﬁcial outcome following sub-
cutaneous treatment with EB that resulted in signiﬁcantly low-
ered incidence of pain-like behavior that was detected in male
rats after a chronic SCI. Various favorable outcomes have been
also reported for systemic EB treatment in other studies (Yune
et al., 2004; Webb et al., 2006; Hubscher et al., 2010; Kachadroka
et al., 2010). Our study suggests that beneﬁcial outcomes may
result, at least partly, by preventing the post-injury toxicity result-
ing from increased dynorphin expression in spinal cord. Several
types of evidence presented in the current study indicate reduced
dynorphin expression after treatment with subcutaneous EB pel-
lets. These include reduced tissue levels of PRDN, reduced count
of PRDN-labeled NeuN positive neurons, a positive correlation
between the tissue levels of PRDN and KOR-P and reduced PRDN
labeling of synapsin I-IR puncta, which represent nerve termi-
nals. In addition, others have shown previously that subcutaneous
EB replacement can reduce the expression of PRDN in the cen-
tral nervous system. For example, EB replacement suppressed
the post-ovariectomy increase in PRDN gene expression in the
adenohypophysis in rats (Spampinato et al., 1995). EB replace-
ment mechanism in ovariectomized mice also reduced the PRDN
expression in the arcuate nucleus by an ERα mediated (Gottsch
et al., 2009).
Note that the present study was limited to male rats since males
constitute 80.7%of the total SCI population (National SpinalCord
Injury Statistical Center, Birmingham,AL, USA – February 2011).
However, the current use of estrogens for therapeutic purposes in
males is limited because of the serious side effects, such as throm-
boembolism (Sayed and Taxel, 2003). There are current clinical
trials of promising new therapeutic agents for potential use in
males known as selective ER modulators, which mimic the effects
of estrogen without their serious side effects (Pickar et al., 2010).
Also note that other indirect effects of systemic EB treatment, such
as reduced levels of testosterone as well as luteinizing and follicu-
lar stimulating hormone, which are observed during EB infusion
(Bagatell et al., 1994), may also contribute to the decreased dynor-
phin levels and/or its beneﬁcial effects. However, the present data,
showing the reduction in the count of PRDN-/NeuN-IR neu-
rons induced by systemic EB treatment in the superﬁcial laminae
where ERα and PRDN co-expression is seen, supports the direct
involvement of EB on dynorphin expression.
EXPRESSION OF PRDN AND KOR-P
The Western blot analysis in this study demonstrates an increase
of PRDN levels in the at level (T5, T6) spinal cord tissues of male
rats with severe chronic (6 weeks) SCI at T8, which is reversed
in animals given subcutaneous EB implants prior to the injury
(shown to result in proestrus-like blood levels of EB upon mea-
surement at the terminal stage). An increase in the synthesis of
PRDN is expected to increase the extracellular levels of the most
abundant form of endogenous κ-opioid in the spinal cord, dynor-
phin A (1–17; Chen et al., 2007), which was studied by measuring
the tissue levels of KOR-P, since phosphorylation at serine 369 of
KOR is dose dependent in response to activation by κ-agonists
(Appleyard et al., 1997; McLaughlin et al., 2003). Our data reveals
a signiﬁcant increase in the KOR-P levels in post-SCI spinal tis-
sues, corresponding to sensitive dermatomes (T5–T8), which is
consistent with increased activity of dynorphinergic terminals in
spinal cord at level. The tissue KOR-P levels after EB treatment
were found not to be signiﬁcantly different from those after the
placebo treatment. In addition, a signiﬁcant positive correlation
between the levels of PRDN and KOR-P in post-SCI spinal cord
tissues (Figure 1C) is found, which indicates that the PRDN levels
positively inﬂuence the levels of KOR-P, an indicator of magnitude
of dynorphin release.
The decreased release of dynorphin with continuous EB treat-
ment may be due to the diminished stores in nerve terminals,
which are indicated by a signiﬁcant reduction in detectable PRDN
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labeling of synapsin I-IR nerve terminals (by ∼67%, as shown
in Figure 4). The reduced PRDN labeling of the nerve terminals
is likely to be associated with the decreased expression of PRDN
within the neurons in the superﬁcial laminae after EB treatment.
In this context, note that the count of PRDN-/NeuN-IR neu-
rons in superﬁcial laminae I and II, showing frequent PRDN/ERα
co-expression, declined by 48% following EB treatment. Another
ﬁndingworthy of note is the absence of a signiﬁcant increase in the
counts of PRDN positive NeuN neurons after the injury relative
to shams. This may be due to the overall loss of neurons following
injury. Hence, it is likely that the signiﬁcantly increased dynorphin
levels detected after injury by theWestern blot analysis may be due
to the increase of its levels in the surviving neurons, axons, and the
nerve terminals.
We propose that EB pretreatment, by preventing increased
dynorphin expression following SCI, is responsible for the
improved behavioral outcome (reduction in the incidence of at
level allodynia) previously reported by our group (Hubscher et al.,
2010) and observed again with the current group of rats.
PRDN EXPRESSION ENHANCES NEURONAL EXCITABILITY VIA
NON-OPIOID MECHANISMS
The immunohistochemical and electron microscopic data shows
that dynorphin is expressed in a subpopulation of glutamatergic
(VGLUT2) nerve terminals at T7 (consistent with Marvizon et al.,
2009), indicating an excitatory phenotype of dynorphin terminals,
which is further supported by the electron microscopic ﬁnding of
the post-synaptic density (Figure 3D; Guillery, 2000). This ﬁnd-
ing is important for understanding the non-opioid basis for the
adverse effects of dynorphin, resulting from increased tissue levels
post-injury. It has been proposed by Laughlin et al. (2001) that
the interaction of dynorphin with NMDARs via multiple bind-
ing sites can produce excitatory responses resulting in nociceptive
behavior and other adverse effects. The non-opioid basis for the
toxic effects of dynorphin is supported by experimental evidence
employing the intrathecal injection of fragments lacking the opi-
oid activity, such as dynorphin A (2–17) and dynorphin A (3–17),
in addition to dynorphin A (1–17) with full opioid activity, all of
which produce persistent adverse effects on sensory, motor and
autonomic functions leading to allodynia, hind limb locomotor
function loss, and bladder function impairment (Long et al., 1988;
Vanderah et al., 1996; Laughlin et al., 1997).
Both theNMDARdependent andNMDAR independentmech-
anisms are found to be responsible for the effects of dynorphin in
pharmacological and in vitro studies (Tang et al., 2000; Laughlin
et al., 2001; Woods et al., 2006). NMDAR independent effects of
dynorphin include increasing Ca++ inﬂux in hybridoma cell lines
of embryonic rat dorsal root ganglia cells, mediated by bradykinin
receptor B2, which was also responsible for nociceptive behavior
after L5, L6 SNL in rats (Lai et al., 2006). The Ca++ inﬂux caused
by dynorphin may also lead to increased release of neurotrans-
mitters (Perney et al., 1986) at the dynorphin terminals, which
are widely distributed. The activation of Ca++ dependent pro-
tein kinase C, following the Ca++ inﬂux produced by dynorphin,
can also cause NMDAR activation (Tang et al., 2000). Consistent
with this hypothesis, the low pharmacological doses of dynor-
phin A (1–13), which increased the Ca++ inﬂux, were shown to
contribute to the post-synaptic enhancement of NMDAR (Skilling
et al., 1992).
Dynorphin also directly activates NMDARs via binding to the
NR1 subunit, which was shown to be responsible for its toxicity
in vivo and in vitro (Woods et al., 2006). According to an emerging
concept, the activity of NMDARs is essential for synaptogene-
sis, experience-dependent synaptic remodeling and long-lasting
changes in synaptic efﬁcacy such as long-term potentiation and
long-termdepression (Lau andZukin, 2007),which is likely to play
important role in the post-injury toxicity of dynorphin in spinal
tissues, since many of the adverse effects of intrathecal dynorphin
are persistent in nature (Long et al., 1988; Vanderah et al., 1996;
Laughlin et al., 1997).
Evidence for increased neuronal activity includes a study using
c-fos, a marker of neuronal activity in gray matter immediately
above the level of injury in a SCImodel exhibiting at level allodynia
(Siddall et al., 1999). Thehypersensitivity of neurons in ventral and
posterior thalamic nuclei evokedby stimulationof at level (T5–T8)
dermatomes in the current model of SCI (Hubscher and Johnson,
2006) suggests increased stimulation of spinothalamic neurons in
the spinal cord. Direct recordings of dorsal horn neurons at cer-
vical (Carlton et al., 2009) and at spinal cord levels immediately
rostral (T8/9; Crown et al., 2008) to a contusion injury at T10
also showed increased responses to various mechanical stimuli,
indicating an injury-induced increase in neuronal activity. The
NMDAR activation is seen in animal models exhibiting upregula-
tion of dynorphin in spinal cord. In S2 and L5/6 SNL models, the
intrathecal injection of the non-competitive inhibitor of NMDAR,
MK-801 suppressed the increased pain response (Malan et al.,
2000;Wang et al., 2001). In the neuropathic painmodel induced by
intrathecal dynorphin injection, intrathecal injection of MK-801
produced transient blockade of the mechanical allodynia (Laugh-
lin et al., 1997). It is important to note that the acute effects
of systemic EB can also reduce activity of NMDARs, which is
independent of genomic mechanisms, such as reduced expression
of dynorphin, as indicated by rapid and reversible inhibition of
NMDAR currents in a hippocampal neuron culture (Weaver et al.,
1997), and may contribute to the overall beneﬁcial effect of EB in
a chronic injury model.
POSSIBLE ATTENUATION OF OPIOID EFFECT IN MODELS WITH
DYNORPHIN UPREGULATION
An increased inhibitory κ-opioid tone, responsible for anti-
nociceptive effect, is demonstrated in an arthritic pain model,
exhibiting increased levels of dynorphin in the lumbar sacral
spinal cord, which showed that hyperalgesia was potentiated by
a κ speciﬁc antagonist, MR2266 (Millan et al., 1985). Note that
the current study shows high levels of KOR-P in spinal tissues
after severe chronic SCI, which is consistent with the development
of desensitization to the effects of KOR activation by dynor-
phin (McLaughlin et al., 2003). Therefore, we argue that although
inhibitory opioid tone may be present as a result of increased tis-
sue levels of dynorphin, promoting anti-nociception as detected
in a previous study (Millan et al., 1985), it is likely to undergo
signiﬁcant attenuation as a result of the desensitization. Absence
of a signiﬁcant role of κ-opioid activity is indicated in a L5/L6
SNL model which did not show difference in the stimulation of
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γ-[35S]GTP binding by κ receptor agonist U69,593 with or
without SNL surgery (Wang et al., 2001).
OTHER BENEFITS OF EB TREATMENT
The maladaptive changes and associated increase in excitability
caused by the elevated levels of tissue dynorphin can plausibly con-
tribute to other consequences of SCI, such as locomotor deﬁcits,
muscle spasticity, sexual dysfunction, autonomic dysreﬂexia, and
bladder and bowel dysfunction (Levi et al., 1995; Widerstrom-
Noga et al., 1999). Note that the potential beneﬁts of EB treatment
on locomotor systems has been studied by several groups within
the context of neuroprotection, as already discussed. Our future
studies will examine the beneﬁts of EB relative to reducing exces-
sive levels of dynorphin, for locomotor as well as other systems
(pelvic visceral function).Alsonote that over-stimulationof motor
neurons can cause spasticity. The development of high excito-
toxic levels of extracellular dynorphinmay contribute to themotor
deﬁcits due to the loss of motor neurons. The increased activity
and/or the loss of sympathetic and the parasympathetic neurons
in thoracic and lumbosacral segments (Jansen et al., 1993; de
Groat, 1998) could contribute to the bladder and/or sexual and/or
autonomic dysfunctions following the SCI.
It is noteworthy that the incidence of ﬁbromyalgia, a chronic
pain condition associated with elevated levels of dynorphin in
cerebrospinal ﬂuid (Vaeroy et al., 1991), increases sharply after
menopause suggesting that decreased estrogen levels may play a
role in its pathogenesis (Waxman and Zatzkis, 1986), which is
consistent with the argument that the beneﬁcial outcomes result
from estrogen replacement.
Also, since increased microglial activity may produce adverse
effects on spinal cord circuitries,which is indicated by the temporal
correlation between abnormal pain response and the proliferation
of Iba-1 positive microglia in spinal cord dorsal horn in a sci-
atic nerve injury model of neuropathic pain (Echeverry et al.,
2008), the potential beneﬁcial effect of EB may be due to the
suppression of adverse microglial activity. This is suggested by
the effect of EB pretreatment on a culture of microglia activated
by lipopolysaccharide (LPS), which prevents injury produced in
the rat mesencephalic primary neuron culture by the conditioned
media from LPS treated microglial culture (Liu et al., 2005).
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